Cortexolone 17α-propionate for hidradenitis suppurativa
- PMID: 32761708
- DOI: 10.1111/dth.14142
Cortexolone 17α-propionate for hidradenitis suppurativa
Comment on
-
Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.JAMA Dermatol. 2020 Jun 1;156(6):621-630. doi: 10.1001/jamadermatol.2020.0465. JAMA Dermatol. 2020. PMID: 32320027 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156:e200465. https://doi.org/10.1001/jamadermatol.2020.0465.
-
- Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045-1058. https://doi.org/10.1016/j.jaad.2019.08.090.
-
- Riis PT, Ring HC, Themstrup L, Jemec GB. The role of androgens and estrogens in hidradenitis suppurativa - a systematic review. Acta Dermatovenerol Croat. 2016;24(4):239-249.
-
- Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M. Cortexolone 17α-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412-418.
-
- Nikolakis G, Kyrgidis A, Zouboulis CC. Is there a role for antiandrogen therapy for hidradenitis suppurativa? A systematic review of published data. Am J Clin Dermatol. 2019;20(4):503-513. https://doi.org/10.1007/s40257-019-00442-w.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
